UniProtKB/Swiss-Prot Q9H9E3 : Variant p.Gly512Arg
Conserved oligomeric Golgi complex subunit 4
Gene: COG4
Feedback ?
Variant information
Variant position:
512
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
LP/P [Disclaimer : Variants classification is intended for research purposes only, not for clinical and diagnostic use . The label disease variant is assigned according to literature reports on probable disease-association that can be based on theoretical reasons. This label must not be considered as a definitive proof for the pathogenic role of a variant. ]
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
From Glycine (G) to Arginine (R) at position 512 (G512R, p.Gly512Arg).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
Change from glycine (G) to large size and basic (R)
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
-2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Variant description:
In SWILS; delayed anterograde vesicular trafficking from the ER to the Golgi and accelerated retrograde vesicular recycling from the Golgi to the ER, leading to a decrease in Golgi volume, as well as morphologic abnormalities with collapse of the Golgi stacks in affected fibroblasts; altered decorin/DCN Golgi-dependent glycosylation; no effect on protein expression.
Any additional useful information about the variant.
Other resources:
Links to websites of interest for the variant.
Sequence information
Variant position:
512
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
785
The length of the canonical sequence.
Location on the sequence:
VLCNKLRMGFPATTFQDIQR
G VTSAVNIMHSSLQQGKFDTK
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
2 – 785
Conserved oligomeric Golgi complex subunit 4
Alternative sequence
338 – 785
Missing. In isoform 2.
Literature citations
A recurrent de novo heterozygous COG4 substitution leads to Saul-Wilson syndrome, disrupted vesicular trafficking, and altered proteoglycan glycosylation.
Ferreira C.R.; Xia Z.J.; Clement A.; Parry D.A.; Davids M.; Taylan F.; Sharma P.; Turgeon C.T.; Blanco-Sanchez B.; Ng B.G.; Logan C.V.; Wolfe L.A.; Solomon B.D.; Cho M.T.; Douglas G.; Carvalho D.R.; Bratke H.; Haug M.G.; Phillips J.B.; Wegner J.; Tiemeyer M.; Aoki K.; Nordgren A.; Hammarsjoe A.; Duker A.L.; Rohena L.; Hove H.B.; Ek J.; Adams D.; Tifft C.J.; Onyekweli T.; Weixel T.; Macnamara E.; Radtke K.; Powis Z.; Earl D.; Gabriel M.; Russi A.H.S.; Brick L.; Kozenko M.; Tham E.; Raymond K.M.; Phillips J.A. III; Tiller G.E.; Wilson W.G.; Hamid R.; Malicdan M.C.V.; Nishimura G.; Grigelioniene G.; Jackson A.; Westerfield M.; Bober M.B.; Gahl W.A.; Freeze H.H.;
Am. J. Hum. Genet. 103:553-567(2018)
Cited for: INVOLVEMENT IN SWILS; VARIANT SWILS ARG-512; CHARACTERIZATION OF VARIANT SWILS ARG-512; FUNCTION; SUBCELLULAR LOCATION;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.